SlideShare a Scribd company logo
1 of 28
Download to read offline
Cartridge –
Based Nucleic
Acid Amplification Test
(CBNAAT)
Dr.M.P. Samrat Abhishek
M.B.B.S.,FICM
District TB Control
Born Robert Heinrich
Herman Koch
11 December 1843
Clausthal,
Kingdom of Hanover
Died 27 May
1910 (aged 66)
Baden-Baden,
Grand Duchy of Baden
Nationality German
Fields Microbiology
•Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis and, less
commonly, by other organisms of the ‘tuberculosis complex’. It is estimated that 3 million
people die from TB each year—the majority of them in developing countries.
• The annual incidence of New cases of all forms of TB (pulmonary and extra-pulmonary)
worldwide is estimated to be approximately 8 million, of which about 95% occur in
developing countries. Many TB cases in developing countries remain
undiscovered. Of the discovered smear-positive cases, less than half complete
treatment.
• Consequently, the estimated prevalence (the total number of tuberculosis cases
at a given time) worldwide is 16 to 20 million, of whom about 8 to 10 million are
sputum smear-positive and highly infectious.
•The number of persons infected with the tuberculosis bacillus is estimated to be 1.7
billion, of which 1.3 billion live in developing countries. In India, more than 40% of adults
are infected with TB, and approximately 1.5 million cases are put on treatment every
year. An estimated 5 lakh deaths from TB occur every year.
INCIDENCE OF TB IN INDIA
o Tuberculosis is one of the deadliest public health
threats today, but there remains a lack of effective
diagnostic tools.
o untreated tb patients remain a source of infection for
other members of community & results in
considerable morbidity & mortality , especially in
PLHIV group.
Screening methods for tuberculosis:
The most widely used method to detect TB is
sputum smear microscopy test, which has a
number of drawbacks including……
• low sensitivity (especially in HIV-positive individuals
and children)
• inability to determine drug-susceptibility
• variable performance that depends on operator
training.
X-Ray especially the digital version serves as the
most sensitive tool but only shows opacities
which is further depends upon the x-ray reader(inter
& intra reader variations of reporting).
 Conventional diagnosis of drug resistant TB
relies on mycobacterial culture and drug
susceptibility testing (DST), a slow and
cumbersome process requiring sequential procedures
for isolation of mycobacteria from clinical specimens.
 Identification of Mycobacterium tuberculosis
complex, and in vitro testing of strain susceptibility to
anti-TB drugs.
During this time patients may be inappropriately
treated, drug-resistant strains may continue to
spread, and amplification of resistance may occur.
The CBNAAT/ Xpert MTB/Rif test is a cartridge-
based fully automated NAAT (nucleic acid
amplification test) for TB case detection and
Rifampicin resistance testing.
Purifies, concentrates, amplifies (by rapid, real-time
PCR) and identifies targeted nucleic acid It sequences
in the TB genome (rpo b), and provides results from
unprocessed sputum samples in less than 2 hours,
with minimal hands-on technical time.
Cbnaat ppt by Dr. Samrat Abhishek
Cbnaat ppt by Dr. Samrat Abhishek
Diagnosis of TB, TBHIV, MDR-
TB and XDR-TB WITH CBNAAT :
Sputum smear microscopy has a particularly low
sensitivity for detecting TB among PLHIV.
This is because people in later stages of HIV infection and
with compromised immune systems often release fewer
organisms into their sputum, at concentrations
below the threshold for visual detection under a
microscope.
For PLHIV with a negative smear microscopy result
but who are still presumed to have TB, bacterial
culture has been the other option.
culture can only be undertaken at central level
laboratories, and results are normally only available
after a number of weeks or months.
Culture is therefore not good enough for people living
with HIV, who need a speedy TB diagnosis and
prompt treatment.
CBNAAT allows for the rapid detection of TB and
resistance to rifampicin in a single test.
It has a sensitivity superior to that of conventional
microscopy or culture on solid media, and is therefore
useful in the diagnosis of TB in HIV co-infected
persons where the sensitivity of microscopy
alone is low.
o The system simultaneously detects resistance to
rifampicin, which is a good and reliable proxy for
MDR TB.
who guide line:
WHO recommends the use of Xpert MTB/RIF as a
primary diagnostic test for all people living with
HIV who have signs and symptoms of TB.
For people with unknown HIV status presenting with
strong clinical evidence of HIV infection.
For people who are seriously ill and suspected of
having TB regardless of HIV status and those at high
risk of MDR-TB.
WHO has issued policy recommendations for the use of Xpert MTB/RIF in the
diagnosis of extrapulmonary TB and rifampicin resistance detection
• Xpert MTB/RIF should be used in preference to conventional microscopy and
culture as the initial diagnostic test in testing cerebrospinal fluid specimens
from patients presumed to have TB meningitis (strong recommendation given
the urgency of rapid diagnosis, very low quality of evidence);
• Xpert MTB/RIF may be used as a replacement test for usual practice
(including conventional microscopy, culture, and/or histopathology) for testing
of specific non-respiratory specimens (lymph nodes and other tissues) from
patients presumed to have extrapulmonary TB (conditional recommendation,
very low quality of evidence).
•For CSF specimens, Xpert MTB/RIF should be preferentially used over culture if the
sample volume is low or additional specimens cannot be obtained, in order to reach
quick diagnosis. If sufficient volume of material is available, concentration methods
should be used to increase yield;
•Individuals presumed to have extrapulmonary TB but with a single Xpert MTB/RIF -
negative result should undergo further diagnostic testing and hence processing of
tissue samples (lymph nodes and other tissues) for Xpert MTB/RIF should include a
decontamination step to enable samples to be concurrently cultures
•Pleural fluid is a suboptimal sample for the bacterial confirmation of pleural TB, using
any method. A pleural biopsy is the preferred sample.
•These recommendations do not apply to stool, urine or blood, given the lack of
data on the utility of Xpert MTB/RIF on these specimens.
CBNAAT SUSPECTS CRITERIA:
A. All PLHIV cases.
B. All MDR close contacts .
C. All retreatment smear negative cases & extra
pulmonary cases.
D. All Peadiatric TB suspect cases.
E. Referral cases from public private partnership.
Samples that are recommended for CBNAAT
are…
Sputum- BAL , Gastric lavage (with out food particles).
Pleural fluid.
Ascitic fluid.
CSF.
FNAC / BIOPSY material.
Mid stream urine.
Stool & blood are not recommended.
Lymph nodes / biopsy: Tissue sample pieces grinded
in a sterile container (tissue grinder).
CSF sample of 0.1 ml to 1 ml is recommended for
cbnaat. Less than 0.1 ml is insufficient sample.
Pleural fluid & asitic fluid of 5 ml is recommended for
cbnaat.
Blood stained & xanthochromic samples may cause
false negative.
All specimens should be transferred to the DTC as
early as possible preferred in a stored condition at 2 –
8 degree centigrade.
Specimen processing
The Xpert MTB/RIF assay can be used directly for CSF
specimens and homogenised extrapulmonary samples (lymph
node biopsies and other tissues) or on decontaminated
specimens if culture is performed concurrently.
Whenever possible, specimens should be transported and stored
at 2 to 8°C prior to
processing (a maximum of 7 days).
conclusion
LPAs are currently limited to detecting resistance to
rifampicin and isoniazid and are suitable only on
smear positive Specimens.
Conventional DST is needed to detect resistance to
anti-TB agents other than rifampicin and isoniazid &
to detect XDR-TB.
conclusion
Overall the LPA test is a reliable, rapid and easy to
perform for the simultaneous detection of RMP and
INH resistance in M.tuberculosis
It is recommend that the LPA should serve as an early
guidance of therapy, which should be followed by a
phenotypic DST confirmation for all suspected MDR-
TB patients.
conclusion
Although Xpert MTB/RIF is suitable for use at all
levels of the health system & does not require
additional laboratory equipment, it requires care in
handling, a stable and uninterrupted electrical supply,
security against theft, adequate storage space & bio-
safety measures.
Xpert MTB/RIF does not eliminate the need for
capacity for conventional TB microscopy, culture and
DST.
conclusion
The Xpert MTB/RIF assay is suitable for diagnosing
TB and detecting RR-TB.
A negative result accurately excludes the possibility of
rifampicin resistance and no further testing is needed
to confirm the negative results. (NPV>99%)
conclusion
Microscopy or culture, or both, remain essential for
monitoring treatment since molecular tests based on
DNA detection have not been shown to be suitable.
Liquid culture, molecular LPAs and the Xpert
MTB/RIF assay should be phased in to programmes in
a way that ensures that the existing capacity for solid
culture and DST is maintained.
Cartridge preparation
XpertMTB-RIFCartridgepreparation.mp4
Sample in cartidge
Cartridge-ROBAL.mov
THANK YOU

More Related Content

What's hot

RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSIS
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSISRECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSIS
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSISANGAN KARMAKAR
 
Recent advances in tuberculosis
Recent advances in tuberculosisRecent advances in tuberculosis
Recent advances in tuberculosisDr Amit Vatkar
 
Xpert MTB/RIF Ultra
Xpert MTB/RIF UltraXpert MTB/RIF Ultra
Xpert MTB/RIF UltraSystemOne
 
Recent advances in Tuberculosis diagnosis
Recent advances in Tuberculosis diagnosisRecent advances in Tuberculosis diagnosis
Recent advances in Tuberculosis diagnosisNishantTawari
 
Newer diagnostic methods for tuberculosis
Newer  diagnostic  methods for tuberculosis  Newer  diagnostic  methods for tuberculosis
Newer diagnostic methods for tuberculosis Shweta Anand
 
Shorter oral bedaquiline regimen 2022 NTEP guidelines
Shorter oral bedaquiline regimen 2022 NTEP guidelinesShorter oral bedaquiline regimen 2022 NTEP guidelines
Shorter oral bedaquiline regimen 2022 NTEP guidelinesAnkur Gupta
 
Laboratory diagnosis of HIV
Laboratory diagnosis of HIVLaboratory diagnosis of HIV
Laboratory diagnosis of HIVNikhil Bansal
 
Laboratory diagnosis of tuberculosis pract.
Laboratory diagnosis of tuberculosis pract.Laboratory diagnosis of tuberculosis pract.
Laboratory diagnosis of tuberculosis pract.deepak deshkar
 
Diagnostic modalities in tuberculosis
Diagnostic modalities in tuberculosisDiagnostic modalities in tuberculosis
Diagnostic modalities in tuberculosisbiplave karki
 
Diagnosis of Tuberculosis
Diagnosis of TuberculosisDiagnosis of Tuberculosis
Diagnosis of TuberculosisRohit Vikas
 
WHO recommended tests of tuberculosis
WHO recommended tests of tuberculosisWHO recommended tests of tuberculosis
WHO recommended tests of tuberculosisprapulla chandra
 
Newer investigations of tuberculosis
Newer investigations of tuberculosisNewer investigations of tuberculosis
Newer investigations of tuberculosisVishnu Ambareesh
 
HIV and TB coinfection
HIV and TB coinfectionHIV and TB coinfection
HIV and TB coinfectionswati2084
 
Newer anti tb drugs
Newer anti tb drugsNewer anti tb drugs
Newer anti tb drugsAnkur Gupta
 

What's hot (20)

RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSIS
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSISRECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSIS
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSIS
 
Xpert MTB/RIF Ultra newer technology past to future DIAGNOSIS OF TUBERCULOSIS
Xpert MTB/RIF Ultranewer technologypast to future DIAGNOSIS OF TUBERCULOSIS Xpert MTB/RIF Ultranewer technologypast to future DIAGNOSIS OF TUBERCULOSIS
Xpert MTB/RIF Ultra newer technology past to future DIAGNOSIS OF TUBERCULOSIS
 
Recent advances in tuberculosis
Recent advances in tuberculosisRecent advances in tuberculosis
Recent advances in tuberculosis
 
Xpert MTB/RIF Ultra
Xpert MTB/RIF UltraXpert MTB/RIF Ultra
Xpert MTB/RIF Ultra
 
Recent advances in Tuberculosis diagnosis
Recent advances in Tuberculosis diagnosisRecent advances in Tuberculosis diagnosis
Recent advances in Tuberculosis diagnosis
 
Gene Xpert & Advances
Gene Xpert & AdvancesGene Xpert & Advances
Gene Xpert & Advances
 
Newer diagnostic methods for tuberculosis
Newer  diagnostic  methods for tuberculosis  Newer  diagnostic  methods for tuberculosis
Newer diagnostic methods for tuberculosis
 
Molecular diagnosis in tuberculosis
Molecular diagnosis in tuberculosisMolecular diagnosis in tuberculosis
Molecular diagnosis in tuberculosis
 
Shorter oral bedaquiline regimen 2022 NTEP guidelines
Shorter oral bedaquiline regimen 2022 NTEP guidelinesShorter oral bedaquiline regimen 2022 NTEP guidelines
Shorter oral bedaquiline regimen 2022 NTEP guidelines
 
Laboratory diagnosis of HIV
Laboratory diagnosis of HIVLaboratory diagnosis of HIV
Laboratory diagnosis of HIV
 
Laboratory diagnosis of tuberculosis pract.
Laboratory diagnosis of tuberculosis pract.Laboratory diagnosis of tuberculosis pract.
Laboratory diagnosis of tuberculosis pract.
 
Diagnostic modalities in tuberculosis
Diagnostic modalities in tuberculosisDiagnostic modalities in tuberculosis
Diagnostic modalities in tuberculosis
 
Diagnosis of Tuberculosis
Diagnosis of TuberculosisDiagnosis of Tuberculosis
Diagnosis of Tuberculosis
 
Tuberculosis & hiv coexistence
Tuberculosis & hiv coexistenceTuberculosis & hiv coexistence
Tuberculosis & hiv coexistence
 
Management of TB 2019
Management of TB 2019Management of TB 2019
Management of TB 2019
 
WHO recommended tests of tuberculosis
WHO recommended tests of tuberculosisWHO recommended tests of tuberculosis
WHO recommended tests of tuberculosis
 
Newer investigations of tuberculosis
Newer investigations of tuberculosisNewer investigations of tuberculosis
Newer investigations of tuberculosis
 
HIV and TB coinfection
HIV and TB coinfectionHIV and TB coinfection
HIV and TB coinfection
 
Resistant tb
Resistant tbResistant tb
Resistant tb
 
Newer anti tb drugs
Newer anti tb drugsNewer anti tb drugs
Newer anti tb drugs
 

Similar to Cbnaat ppt by Dr. Samrat Abhishek

Current tuberculosis management in short
Current tuberculosis management in shortCurrent tuberculosis management in short
Current tuberculosis management in shortSubhajit Ghosh
 
Molecular assay in tuberculosis.pptx
Molecular assay in tuberculosis.pptxMolecular assay in tuberculosis.pptx
Molecular assay in tuberculosis.pptxyogeshtomar32
 
Revised national tuberculosis control programme
Revised national tuberculosis control programmeRevised national tuberculosis control programme
Revised national tuberculosis control programmeHonorato444
 
Anti tubercular therapy in Skeletal TB
Anti tubercular therapy in Skeletal TBAnti tubercular therapy in Skeletal TB
Anti tubercular therapy in Skeletal TBNeelaBiradar
 
[final] - TB DIAGNOSIS ECHO - 20TH MARCH 2023.pptx
[final] - TB DIAGNOSIS  ECHO - 20TH MARCH 2023.pptx[final] - TB DIAGNOSIS  ECHO - 20TH MARCH 2023.pptx
[final] - TB DIAGNOSIS ECHO - 20TH MARCH 2023.pptxAngetileKasanga
 
Tb diagnosis and treatment an update
Tb diagnosis and treatment   an updateTb diagnosis and treatment   an update
Tb diagnosis and treatment an updateSomnath Das Gupta
 
Newer methods in diagnosis of tuberculosis in children
Newer methods in diagnosis of tuberculosis in childrenNewer methods in diagnosis of tuberculosis in children
Newer methods in diagnosis of tuberculosis in childrenDr Naveen kumar
 
what is new in prevention, diagnosis and treatment of tuberculosis tb short.pptx
what is new in prevention, diagnosis and treatment of tuberculosis tb short.pptxwhat is new in prevention, diagnosis and treatment of tuberculosis tb short.pptx
what is new in prevention, diagnosis and treatment of tuberculosis tb short.pptxPathKind Labs
 
Investigations in Tuberculosis and advances
Investigations in Tuberculosis and advancesInvestigations in Tuberculosis and advances
Investigations in Tuberculosis and advancesNirish Vaidya
 
World TB Day 2017
World TB Day 2017World TB Day 2017
World TB Day 2017Sesha Sai
 
Tb sure ultra short july 2019
Tb sure ultra short july 2019Tb sure ultra short july 2019
Tb sure ultra short july 2019PathKind Labs
 
Dr Rishabh Algorithm.pptx
Dr Rishabh Algorithm.pptxDr Rishabh Algorithm.pptx
Dr Rishabh Algorithm.pptxEx WHO/USAID
 
Managing OIs and Comobidities.pptx
Managing OIs and Comobidities.pptxManaging OIs and Comobidities.pptx
Managing OIs and Comobidities.pptxshillahhungwe
 
labaratory diagnosis of tuberulosis.
labaratory diagnosis of tuberulosis.labaratory diagnosis of tuberulosis.
labaratory diagnosis of tuberulosis.Tarun Prudvi Betha
 
Newer diagnostic methods in tuberculosis detection
Newer diagnostic methods in tuberculosis detectionNewer diagnostic methods in tuberculosis detection
Newer diagnostic methods in tuberculosis detectionApollo Hospitals
 

Similar to Cbnaat ppt by Dr. Samrat Abhishek (20)

Lab diagnosis of TB
Lab diagnosis of TBLab diagnosis of TB
Lab diagnosis of TB
 
Detection of HIV-TB co infection New approaches
Detection of HIV-TB co infectionNew approachesDetection of HIV-TB co infectionNew approaches
Detection of HIV-TB co infection New approaches
 
Current tuberculosis management in short
Current tuberculosis management in shortCurrent tuberculosis management in short
Current tuberculosis management in short
 
Molecular assay in tuberculosis.pptx
Molecular assay in tuberculosis.pptxMolecular assay in tuberculosis.pptx
Molecular assay in tuberculosis.pptx
 
Revised national tuberculosis control programme
Revised national tuberculosis control programmeRevised national tuberculosis control programme
Revised national tuberculosis control programme
 
Anti tubercular therapy in Skeletal TB
Anti tubercular therapy in Skeletal TBAnti tubercular therapy in Skeletal TB
Anti tubercular therapy in Skeletal TB
 
[final] - TB DIAGNOSIS ECHO - 20TH MARCH 2023.pptx
[final] - TB DIAGNOSIS  ECHO - 20TH MARCH 2023.pptx[final] - TB DIAGNOSIS  ECHO - 20TH MARCH 2023.pptx
[final] - TB DIAGNOSIS ECHO - 20TH MARCH 2023.pptx
 
Tb diagnosis and treatment an update
Tb diagnosis and treatment   an updateTb diagnosis and treatment   an update
Tb diagnosis and treatment an update
 
Newer methods in diagnosis of tuberculosis in children
Newer methods in diagnosis of tuberculosis in childrenNewer methods in diagnosis of tuberculosis in children
Newer methods in diagnosis of tuberculosis in children
 
what is new in prevention, diagnosis and treatment of tuberculosis tb short.pptx
what is new in prevention, diagnosis and treatment of tuberculosis tb short.pptxwhat is new in prevention, diagnosis and treatment of tuberculosis tb short.pptx
what is new in prevention, diagnosis and treatment of tuberculosis tb short.pptx
 
Investigations in Tuberculosis and advances
Investigations in Tuberculosis and advancesInvestigations in Tuberculosis and advances
Investigations in Tuberculosis and advances
 
World TB Day 2017
World TB Day 2017World TB Day 2017
World TB Day 2017
 
Tb sure ultra short july 2019
Tb sure ultra short july 2019Tb sure ultra short july 2019
Tb sure ultra short july 2019
 
Dr Rishabh Algorithm.pptx
Dr Rishabh Algorithm.pptxDr Rishabh Algorithm.pptx
Dr Rishabh Algorithm.pptx
 
Managing OIs and Comobidities.pptx
Managing OIs and Comobidities.pptxManaging OIs and Comobidities.pptx
Managing OIs and Comobidities.pptx
 
Rntcp updates
Rntcp updatesRntcp updates
Rntcp updates
 
Rntcp update
Rntcp update Rntcp update
Rntcp update
 
Mdr xdr TB
Mdr xdr TBMdr xdr TB
Mdr xdr TB
 
labaratory diagnosis of tuberulosis.
labaratory diagnosis of tuberulosis.labaratory diagnosis of tuberulosis.
labaratory diagnosis of tuberulosis.
 
Newer diagnostic methods in tuberculosis detection
Newer diagnostic methods in tuberculosis detectionNewer diagnostic methods in tuberculosis detection
Newer diagnostic methods in tuberculosis detection
 

Recently uploaded

SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 

Recently uploaded (20)

SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 

Cbnaat ppt by Dr. Samrat Abhishek

  • 1. Cartridge – Based Nucleic Acid Amplification Test (CBNAAT) Dr.M.P. Samrat Abhishek M.B.B.S.,FICM District TB Control
  • 2. Born Robert Heinrich Herman Koch 11 December 1843 Clausthal, Kingdom of Hanover Died 27 May 1910 (aged 66) Baden-Baden, Grand Duchy of Baden Nationality German Fields Microbiology
  • 3. •Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis and, less commonly, by other organisms of the ‘tuberculosis complex’. It is estimated that 3 million people die from TB each year—the majority of them in developing countries. • The annual incidence of New cases of all forms of TB (pulmonary and extra-pulmonary) worldwide is estimated to be approximately 8 million, of which about 95% occur in developing countries. Many TB cases in developing countries remain undiscovered. Of the discovered smear-positive cases, less than half complete treatment. • Consequently, the estimated prevalence (the total number of tuberculosis cases at a given time) worldwide is 16 to 20 million, of whom about 8 to 10 million are sputum smear-positive and highly infectious. •The number of persons infected with the tuberculosis bacillus is estimated to be 1.7 billion, of which 1.3 billion live in developing countries. In India, more than 40% of adults are infected with TB, and approximately 1.5 million cases are put on treatment every year. An estimated 5 lakh deaths from TB occur every year. INCIDENCE OF TB IN INDIA
  • 4. o Tuberculosis is one of the deadliest public health threats today, but there remains a lack of effective diagnostic tools. o untreated tb patients remain a source of infection for other members of community & results in considerable morbidity & mortality , especially in PLHIV group.
  • 5. Screening methods for tuberculosis: The most widely used method to detect TB is sputum smear microscopy test, which has a number of drawbacks including…… • low sensitivity (especially in HIV-positive individuals and children) • inability to determine drug-susceptibility • variable performance that depends on operator training.
  • 6. X-Ray especially the digital version serves as the most sensitive tool but only shows opacities which is further depends upon the x-ray reader(inter & intra reader variations of reporting).  Conventional diagnosis of drug resistant TB relies on mycobacterial culture and drug susceptibility testing (DST), a slow and cumbersome process requiring sequential procedures for isolation of mycobacteria from clinical specimens.
  • 7.  Identification of Mycobacterium tuberculosis complex, and in vitro testing of strain susceptibility to anti-TB drugs. During this time patients may be inappropriately treated, drug-resistant strains may continue to spread, and amplification of resistance may occur.
  • 8. The CBNAAT/ Xpert MTB/Rif test is a cartridge- based fully automated NAAT (nucleic acid amplification test) for TB case detection and Rifampicin resistance testing. Purifies, concentrates, amplifies (by rapid, real-time PCR) and identifies targeted nucleic acid It sequences in the TB genome (rpo b), and provides results from unprocessed sputum samples in less than 2 hours, with minimal hands-on technical time.
  • 11. Diagnosis of TB, TBHIV, MDR- TB and XDR-TB WITH CBNAAT : Sputum smear microscopy has a particularly low sensitivity for detecting TB among PLHIV. This is because people in later stages of HIV infection and with compromised immune systems often release fewer organisms into their sputum, at concentrations below the threshold for visual detection under a microscope.
  • 12. For PLHIV with a negative smear microscopy result but who are still presumed to have TB, bacterial culture has been the other option. culture can only be undertaken at central level laboratories, and results are normally only available after a number of weeks or months. Culture is therefore not good enough for people living with HIV, who need a speedy TB diagnosis and prompt treatment.
  • 13. CBNAAT allows for the rapid detection of TB and resistance to rifampicin in a single test. It has a sensitivity superior to that of conventional microscopy or culture on solid media, and is therefore useful in the diagnosis of TB in HIV co-infected persons where the sensitivity of microscopy alone is low. o The system simultaneously detects resistance to rifampicin, which is a good and reliable proxy for MDR TB.
  • 14. who guide line: WHO recommends the use of Xpert MTB/RIF as a primary diagnostic test for all people living with HIV who have signs and symptoms of TB. For people with unknown HIV status presenting with strong clinical evidence of HIV infection. For people who are seriously ill and suspected of having TB regardless of HIV status and those at high risk of MDR-TB.
  • 15. WHO has issued policy recommendations for the use of Xpert MTB/RIF in the diagnosis of extrapulmonary TB and rifampicin resistance detection • Xpert MTB/RIF should be used in preference to conventional microscopy and culture as the initial diagnostic test in testing cerebrospinal fluid specimens from patients presumed to have TB meningitis (strong recommendation given the urgency of rapid diagnosis, very low quality of evidence); • Xpert MTB/RIF may be used as a replacement test for usual practice (including conventional microscopy, culture, and/or histopathology) for testing of specific non-respiratory specimens (lymph nodes and other tissues) from patients presumed to have extrapulmonary TB (conditional recommendation, very low quality of evidence).
  • 16. •For CSF specimens, Xpert MTB/RIF should be preferentially used over culture if the sample volume is low or additional specimens cannot be obtained, in order to reach quick diagnosis. If sufficient volume of material is available, concentration methods should be used to increase yield; •Individuals presumed to have extrapulmonary TB but with a single Xpert MTB/RIF - negative result should undergo further diagnostic testing and hence processing of tissue samples (lymph nodes and other tissues) for Xpert MTB/RIF should include a decontamination step to enable samples to be concurrently cultures •Pleural fluid is a suboptimal sample for the bacterial confirmation of pleural TB, using any method. A pleural biopsy is the preferred sample. •These recommendations do not apply to stool, urine or blood, given the lack of data on the utility of Xpert MTB/RIF on these specimens.
  • 17. CBNAAT SUSPECTS CRITERIA: A. All PLHIV cases. B. All MDR close contacts . C. All retreatment smear negative cases & extra pulmonary cases. D. All Peadiatric TB suspect cases. E. Referral cases from public private partnership.
  • 18. Samples that are recommended for CBNAAT are… Sputum- BAL , Gastric lavage (with out food particles). Pleural fluid. Ascitic fluid. CSF. FNAC / BIOPSY material. Mid stream urine. Stool & blood are not recommended.
  • 19. Lymph nodes / biopsy: Tissue sample pieces grinded in a sterile container (tissue grinder). CSF sample of 0.1 ml to 1 ml is recommended for cbnaat. Less than 0.1 ml is insufficient sample. Pleural fluid & asitic fluid of 5 ml is recommended for cbnaat. Blood stained & xanthochromic samples may cause false negative. All specimens should be transferred to the DTC as early as possible preferred in a stored condition at 2 – 8 degree centigrade.
  • 20. Specimen processing The Xpert MTB/RIF assay can be used directly for CSF specimens and homogenised extrapulmonary samples (lymph node biopsies and other tissues) or on decontaminated specimens if culture is performed concurrently. Whenever possible, specimens should be transported and stored at 2 to 8°C prior to processing (a maximum of 7 days).
  • 21. conclusion LPAs are currently limited to detecting resistance to rifampicin and isoniazid and are suitable only on smear positive Specimens. Conventional DST is needed to detect resistance to anti-TB agents other than rifampicin and isoniazid & to detect XDR-TB.
  • 22. conclusion Overall the LPA test is a reliable, rapid and easy to perform for the simultaneous detection of RMP and INH resistance in M.tuberculosis It is recommend that the LPA should serve as an early guidance of therapy, which should be followed by a phenotypic DST confirmation for all suspected MDR- TB patients.
  • 23. conclusion Although Xpert MTB/RIF is suitable for use at all levels of the health system & does not require additional laboratory equipment, it requires care in handling, a stable and uninterrupted electrical supply, security against theft, adequate storage space & bio- safety measures. Xpert MTB/RIF does not eliminate the need for capacity for conventional TB microscopy, culture and DST.
  • 24. conclusion The Xpert MTB/RIF assay is suitable for diagnosing TB and detecting RR-TB. A negative result accurately excludes the possibility of rifampicin resistance and no further testing is needed to confirm the negative results. (NPV>99%)
  • 25. conclusion Microscopy or culture, or both, remain essential for monitoring treatment since molecular tests based on DNA detection have not been shown to be suitable. Liquid culture, molecular LPAs and the Xpert MTB/RIF assay should be phased in to programmes in a way that ensures that the existing capacity for solid culture and DST is maintained.